The CFO of Repligen (RGEN) is Selling Shares
Yesterday, the CFO of Repligen (RGEN), Jon Snodgres, sold shares of RGEN for $92.68K.
In addition to Jon Snodgres, 2 other RGEN executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Repligen’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $76.09 million and quarterly net profit of $9.82 million. In comparison, last year the company earned revenue of $60.63 million and had a net profit of $8.05 million. The company has a one-year high of $143.93 and a one-year low of $65.63. Currently, Repligen has an average volume of 463.31K.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $133.17, reflecting a 0.8% upside.
The insider sentiment on Repligen has been negative according to 28 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.